HUP0103648A2 - Eljárás katéteralakú revascularisatio megelőzésére vagy késleltetésére - Google Patents
Eljárás katéteralakú revascularisatio megelőzésére vagy késleltetéséreInfo
- Publication number
- HUP0103648A2 HUP0103648A2 HU0103648A HUP0103648A HUP0103648A2 HU P0103648 A2 HUP0103648 A2 HU P0103648A2 HU 0103648 A HU0103648 A HU 0103648A HU P0103648 A HUP0103648 A HU P0103648A HU P0103648 A2 HUP0103648 A2 HU P0103648A2
- Authority
- HU
- Hungary
- Prior art keywords
- cholesterol
- preventing
- delaying
- catheter
- lowering agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000000250 revascularization Effects 0.000 title abstract 3
- 239000003529 anticholesteremic agent Substances 0.000 abstract 3
- 229940127226 anticholesterol agent Drugs 0.000 abstract 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- 208000029078 coronary artery disease Diseases 0.000 abstract 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 abstract 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 229960000516 bezafibrate Drugs 0.000 abstract 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 abstract 1
- 229960002174 ciprofibrate Drugs 0.000 abstract 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 abstract 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940125753 fibrate Drugs 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- 229960003627 gemfibrozil Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Surgical Instruments (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A találmány tárgya eljárás katéter alakú revascularisatio szükségesséválásának megelőzésére vagy késleltetésére szívkoszorúér-megbetegedésben szenvedő és ilyen kezelést igénylő betegekben,amelynek során agresszív lipidcsökkentést okozó menynyiségben egykoleszterincsökkentő szert adnak be. Az eljárást előnyösen úgy hajtjákvégre, hogy az eljárás során egy a HMG-CoA reduktáz inhibitoroksztatin osztályából kiválasztott koleszterincsökkentő szert, példáulatorvasztatint, pravasztatint, szimvasztatint, fluvasztatin vagymevasztatint adnak be. A beadható egyéb koleszterincsökkentő szerekközé tartoznak a fibrát osztály tagjai, amilyen például a gemfibrozil,a ciprofibrát és bezafibrát. Egy további megoldás értelmében az LDLkoleszterinnek a találmány szerinti agresszív mértékű csökkentéséhezegy karboxi-éter koleszterincsökkentő szert alkalmaznak, és ily módonelőzik meg vagy késleltetik egy szívkoszorúér-megbetegedésben szenvedőbetegben a katéteralapú revascularisatio szükségessé válását. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10245798P | 1998-09-30 | 1998-09-30 | |
| PCT/US1999/015385 WO2000018395A1 (en) | 1998-09-30 | 1999-07-08 | Method for preventing or delaying catheter-based revascularization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0103648A2 true HUP0103648A2 (hu) | 2003-08-28 |
| HUP0103648A3 HUP0103648A3 (en) | 2003-10-28 |
Family
ID=22289955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103648A HUP0103648A3 (en) | 1998-09-30 | 1999-07-08 | Method for preventing or delaying catheter-based revascularization |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20080119561A1 (hu) |
| EP (1) | EP1117392B1 (hu) |
| JP (1) | JP2002525321A (hu) |
| KR (1) | KR20010079955A (hu) |
| CN (1) | CN1197565C (hu) |
| AP (1) | AP1708A (hu) |
| AT (1) | ATE260100T1 (hu) |
| AU (1) | AU768474B2 (hu) |
| BG (1) | BG105471A (hu) |
| BR (1) | BR9914098A (hu) |
| CA (1) | CA2343299C (hu) |
| CZ (1) | CZ20011035A3 (hu) |
| DE (1) | DE69915084T2 (hu) |
| DK (1) | DK1117392T3 (hu) |
| EA (1) | EA007427B1 (hu) |
| EE (1) | EE200100199A (hu) |
| ES (1) | ES2214872T3 (hu) |
| HK (1) | HK1042436A1 (hu) |
| HR (1) | HRP20010236A2 (hu) |
| HU (1) | HUP0103648A3 (hu) |
| ID (1) | ID30255A (hu) |
| IL (2) | IL141953A0 (hu) |
| IS (1) | IS5889A (hu) |
| NO (1) | NO20011615L (hu) |
| NZ (1) | NZ510500A (hu) |
| OA (1) | OA11787A (hu) |
| PL (1) | PL346980A1 (hu) |
| PT (1) | PT1117392E (hu) |
| SI (1) | SI1117392T1 (hu) |
| SK (1) | SK4122001A3 (hu) |
| TR (1) | TR200100901T2 (hu) |
| UA (1) | UA73292C2 (hu) |
| WO (1) | WO2000018395A1 (hu) |
| YU (1) | YU23901A (hu) |
| ZA (1) | ZA200102230B (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001078747A1 (de) * | 2000-04-18 | 2001-10-25 | Bayer Aktiengesellschaft | Verwendung von cse-hemmern zur behandlung von herzinsuffizienz |
| CA2414783A1 (en) * | 2000-07-14 | 2002-01-24 | Warner-Lambert Company | Treatment of eating disorders using carboxyalkylethers |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| WO1995013063A1 (en) * | 1993-11-09 | 1995-05-18 | Merck & Co., Inc. | HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION |
| US5957916A (en) * | 1994-05-25 | 1999-09-28 | The Trustees Of Columbia University In The City Of New York | Myocardial revascularization through the endocardial surface using a laser |
| US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| CN1217656C (zh) * | 1995-11-02 | 2005-09-07 | 沃尼尔·朗伯公司 | 用于调节脂浓度的方法和药物组合物 |
| SE506272C2 (sv) * | 1996-03-18 | 1997-11-24 | Paul Edholm | Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild |
| IL117702A0 (en) * | 1996-03-28 | 1996-07-23 | Tel Aviv Medical Center Resear | Drug for hyperlipoproteinemia |
| WO1998001100A2 (en) * | 1996-07-09 | 1998-01-15 | Merck & Co., Inc. | Method for treating homozygous familial hypercholesterolemia |
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
-
1999
- 1999-07-08 AP APAP/P/2001/002112A patent/AP1708A/en active
- 1999-07-08 PL PL99346980A patent/PL346980A1/xx not_active Application Discontinuation
- 1999-07-08 DK DK99933763T patent/DK1117392T3/da active
- 1999-07-08 NZ NZ510500A patent/NZ510500A/xx unknown
- 1999-07-08 ES ES99933763T patent/ES2214872T3/es not_active Expired - Lifetime
- 1999-07-08 TR TR2001/00901T patent/TR200100901T2/xx unknown
- 1999-07-08 WO PCT/US1999/015385 patent/WO2000018395A1/en not_active Application Discontinuation
- 1999-07-08 CZ CZ20011035A patent/CZ20011035A3/cs unknown
- 1999-07-08 OA OA1200100080A patent/OA11787A/en unknown
- 1999-07-08 KR KR1020017004021A patent/KR20010079955A/ko active Search and Examination
- 1999-07-08 EP EP99933763A patent/EP1117392B1/en not_active Revoked
- 1999-07-08 CA CA002343299A patent/CA2343299C/en not_active Expired - Fee Related
- 1999-07-08 SI SI9930535T patent/SI1117392T1/xx unknown
- 1999-07-08 PT PT99933763T patent/PT1117392E/pt unknown
- 1999-07-08 DE DE69915084T patent/DE69915084T2/de not_active Revoked
- 1999-07-08 ID IDW20010902A patent/ID30255A/id unknown
- 1999-07-08 BR BR9914098-5A patent/BR9914098A/pt not_active Application Discontinuation
- 1999-07-08 JP JP2000571914A patent/JP2002525321A/ja active Pending
- 1999-07-08 AT AT99933763T patent/ATE260100T1/de not_active IP Right Cessation
- 1999-07-08 EE EEP200100199A patent/EE200100199A/xx unknown
- 1999-07-08 IL IL14195399A patent/IL141953A0/xx active IP Right Grant
- 1999-07-08 EA EA200100370A patent/EA007427B1/ru not_active IP Right Cessation
- 1999-07-08 YU YU23901A patent/YU23901A/sh unknown
- 1999-07-08 HU HU0103648A patent/HUP0103648A3/hu unknown
- 1999-07-08 SK SK412-2001A patent/SK4122001A3/sk unknown
- 1999-07-08 AU AU49750/99A patent/AU768474B2/en not_active Ceased
- 1999-07-08 CN CNB998116297A patent/CN1197565C/zh not_active Expired - Fee Related
- 1999-08-07 UA UA2001042933A patent/UA73292C2/uk unknown
-
2001
- 2001-03-12 IL IL141953A patent/IL141953A/en not_active IP Right Cessation
- 2001-03-14 IS IS5889A patent/IS5889A/is unknown
- 2001-03-16 ZA ZA200102230A patent/ZA200102230B/en unknown
- 2001-03-29 HR HR20010236A patent/HRP20010236A2/hr not_active Application Discontinuation
- 2001-03-29 NO NO20011615A patent/NO20011615L/no not_active Application Discontinuation
- 2001-04-25 BG BG105471A patent/BG105471A/xx unknown
-
2002
- 2002-05-31 HK HK02104071A patent/HK1042436A1/xx not_active IP Right Cessation
-
2007
- 2007-11-28 US US11/946,217 patent/US20080119561A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
| HUP0303923A2 (hu) | Szterin abszorpció inhibitor(ok)kombinációi kardiovaszkuláris szerekkel vaszkuláris kondíciók kezelésére és a kombinációt tartalmazó készítmények | |
| HUP0303083A2 (hu) | CETP-gátló és atorvasztatin terápiás kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0104240A2 (hu) | Eljárás ateroszklerozis kezelésére egy aP2 inhibítor vagy kombinációja alkalmazásával | |
| BRPI0518398A2 (pt) | Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| MX2009003921A (es) | Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. | |
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| Kastelein | The future of best practice | |
| JP2002508320A5 (hu) | ||
| Rubba | Effects of atorvastatin on the different phases of atherogenesis | |
| KR950031063A (ko) | 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법 | |
| BR9813542A (pt) | Combinações de estatina-éter carboxialquìlico | |
| Wierzbicki | Atorvastatin | |
| CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
| Hess et al. | Pharmacology and clinical experience with simvastatin | |
| HUP0103648A2 (hu) | Eljárás katéteralakú revascularisatio megelőzésére vagy késleltetésére | |
| WO2003045311A3 (en) | Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts | |
| Marcus | Lipid disorders in patients with Type 2 diabetes: meeting the challenges of early, aggressive treatment | |
| Stein | Identification and treatment of individuals at high risk of coronary heart disease | |
| JP2003524582A5 (hu) | ||
| Kataria et al. | Statins: the paradigm shift in periodontal regeneration | |
| GB2371748A (en) | HMG-COA reductase inhibitor extended release formulation | |
| JP2002525321A5 (ja) | カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用 | |
| HUP0301728A2 (hu) | HMG-CoA reduktázt gátló gyógyászati készítmények és alkalmazásuk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |